Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets.</li><li>Although still early in its rollout, there are now signs that Pepaxti may become a commercial success in Europe.</li><li>The rights issue of SEK150m announced at the same time should cover operations through 2026 and until there is a positive cash flow.</li></ul>

Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets.Although still early in its rollout, there are now signs that Pepaxti may become a commercial success in Europe.The rights issue of SEK150m announced at the same time should cover operations through 2026 and until there is a positive cash flow.

Oncopeptides Q2 2025: Funded Until Profitability